SPPI loses early gains

SPPI certainly enjoyed an early boost from news of its positive study results for Zevalin. Seems though that the market’s enthusiasm wore off over the course of the day. The study was quite small and it will clearly take some time to replicate the results in a larger cohort – this study involved 2-year progression free survival. Intra-day high was $15.98 but SPPI closed at $15.36.

ASTX and AMRN both closed up on Friday’s close while CRIS closed down slightly.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s